<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-42186" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mycoplasma pneumoniae&#x02013;Induced Rash and Mucositis (MIRM)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Frantz</surname>
            <given-names>Garrett F.</given-names>
          </name>
          <aff>Baylor Scott and White</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McAninch</surname>
            <given-names>Scott A.</given-names>
          </name>
          <aff>Baylor Scott &#x00026; White Health Care</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Garrett Frantz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Scott McAninch declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-42186.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p><italic toggle="yes">Mycoplasma pneumoniae </italic>is a common respiratory pathogen responsible for approximately 10% of all cases of community-acquired pneumonia. This bacterium is more prevalent&#x000a0;in children and young adults.&#x000a0;Aside from respiratory manifestations, <italic toggle="yes">M pneumoniae</italic> causes extrapulmonary syndromes, affecting approximately 25% of patients. These syndromes include cold-agglutinin hemolytic anemia, arthritis, pericarditis, thrombosis, and mucocutaneous manifestations.</p>
        <p>Mucocutaneous eruptions, characterized by rashes affecting both mucous membrane and skin, can manifest as urticaria, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms, stemming from varied causes. However, accurately classifying these rashes in association with <italic toggle="yes">M pneumoniae</italic> infections has proven challenging.&#x000a0;Recently, a distinct pattern of mucocutaneous rash&#x000a0;associated with <italic toggle="yes">M pneumoniae</italic> respiratory infections has proposed an additional mucocutaneous eruption entity, which is&#x000a0;<italic toggle="yes">Mycoplasma</italic>
<italic toggle="yes">pneumoniae</italic>&#x02013;induced rash and mucositis (MIRM).&#x000a0;Diagnosing MIRM typically entails assessing recent or concurrent respiratory symptoms, with laboratory tests confirming <italic toggle="yes">Mycoplasma</italic> involvement. This activity reviews&#x000a0;the etiology and pathophysiology of <italic toggle="yes">Mycoplasma</italic> mucositis while emphasizing the crucial role of the interprofessional healthcare team in achieving optimal patient outcomes through effective management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical features and characteristic manifestations of <italic toggle="yes">Mycoplasma pneumoniae</italic>&#x02013;induced rash and mucositis to facilitate accurate diagnosis.</p></list-item><list-item><p>Implement evidence-based management strategies for <italic toggle="yes">Mycoplasma pneumoniae</italic>&#x02013;induced&#x000a0;rash and mucositis, including antibiotic therapy and supportive care, to optimize patient outcomes.</p></list-item><list-item><p>Select appropriate pharmacological interventions for the treatment of <italic toggle="yes">Mycoplasma pneumoniae</italic>&#x02013;induced&#x000a0;rash and mucositis, considering factors such as antibiotic resistance patterns and patient comorbidities.</p></list-item><list-item><p>Collaborate with interprofessional healthcare team members, including infectious disease specialists, dermatologists, and intensivists, to provide comprehensive care for patients with <italic toggle="yes">Mycoplasma pneumoniae</italic>&#x02013;induced&#x000a0;rash and mucositis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42186&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42186">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-42186.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Mycoplasma pneumoniae&#x000a0;</italic>is a common respiratory pathogen responsible for approximately 10% of all cases of community-acquired pneumonia, with rates rising as high as 37% among children in certain studies and geographic areas.<xref ref-type="bibr" rid="article-42186.r1">[1]</xref><xref ref-type="bibr" rid="article-42186.r2">[2]</xref> This bacterium is more prevalent&#x000a0;in children and young adults.&#x000a0;Aside from respiratory manifestations,&#x000a0;<italic toggle="yes">M pneumoniae</italic>&#x000a0;causes extrapulmonary syndromes, affecting approximately 25% of patients.<xref ref-type="bibr" rid="article-42186.r2">[2]</xref><xref ref-type="bibr" rid="article-42186.r3">[3]</xref>&#x000a0;These syndromes include cold-agglutinin hemolytic anemia, arthritis, pericarditis, thrombosis, and mucocutaneous manifestations. Mucocutaneous eruptions, characterized by rashes affecting both mucous membrane and skin, have varied inciting etiologies, including infectious, frequently viral, drug-induced reactions, and autoimmune factors.<xref ref-type="bibr" rid="article-42186.r4">[4]</xref><xref ref-type="bibr" rid="article-42186.r5">[5]</xref>&#x000a0;</p>
        <p>Previously, <italic toggle="yes">M pneumoniae</italic> infections have been associated with rashes and mucocutaneous manifestations such as urticaria, erythema multiforme, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS).<xref ref-type="bibr" rid="article-42186.r6">[6]</xref><xref ref-type="bibr" rid="article-42186.r7">[7]</xref> However, accurately classifying these rashes associated with&#x000a0;<italic toggle="yes">M pneumoniae</italic>&#x000a0;infections has proven challenging, leading to considerable controversy in the literature. Recently, a distinct pattern of mucocutaneous rash linked to <italic toggle="yes">M pneumoniae</italic> respiratory infections has spurred the proposal for a novel mucocutaneous entity,&#x000a0;coined&#x000a0;<italic toggle="yes">Mycoplasma pneumoniae&#x02013;</italic>Induced rash and mucositis (or MIRM) by Canavan et al in 2015 in a systematic review.<xref ref-type="bibr" rid="article-42186.r8">[8]</xref><xref ref-type="bibr" rid="article-42186.r9">[9]</xref><xref ref-type="bibr" rid="article-42186.r10">[10]</xref></p>
      </sec>
      <sec id="article-42186.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">M pneumoniae</italic>&#x000a0;infections can lead to both pulmonary and extra-pulmonary diseases.<xref ref-type="bibr" rid="article-42186.r11">[11]</xref> These extra-pulmonary conditions encompass vasculitides, neurological complications, immunological disorders, thrombotic events, and mucocutaneous manifestations. Notably, mucocutaneous manifestations occur in approximately 25% of patients with&#x000a0;<italic toggle="yes">M&#x000a0;pneumonia&#x000a0;</italic>infections.<xref ref-type="bibr" rid="article-42186.r12">[12]</xref></p>
        <p>MIRM, a recently identified mucocutaneous entity, was introduced and coined in a 2015 systematic review by Canavan et al.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref> This review, comprising 202 cases of <italic toggle="yes">M pneumoniae</italic>-associated erythema multiforme, SJS, and mucositis without rash, delineated the distinct features of MIRM.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;MIRM is&#x000a0;characterized by prominent mucositis with comparatively less cutaneous involvement than other mucocutaneous syndromes associated with <italic toggle="yes">M pneumoniae</italic>, such as&#x000a0;urticaria, erythema nodosum, erythema multiforme, SJS, TEN, and DRESS.<xref ref-type="bibr" rid="article-42186.r6">[6]</xref><xref ref-type="bibr" rid="article-42186.r7">[7]</xref><xref ref-type="bibr" rid="article-42186.r14">[14]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-42186.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p><italic toggle="yes">M pneumoniae</italic>&#x000a0;is&#x000a0;a prevalent respiratory pathogen, accounting for about 10% of all cases of community-acquired pneumonia. This bacterium can lead to extrapulmonary syndromes in roughly 25% of patients, which include cold-agglutinin hemolytic anemia, arthritis, pericarditis, thrombosis, and mucocutaneous manifestations.<xref ref-type="bibr" rid="article-42186.r2">[2]</xref><xref ref-type="bibr" rid="article-42186.r3">[3]</xref>&#x000a0;The hallmark of&#x000a0;MIRM is the involvement of the mucosa, which typically manifests in the urogenital and oral regions with ulcerations, vesicles, bullae, and ocular involvement. These symptoms often include conjunctivitis and, in severe instances, may lead to conjunctival ulceration and pseudomembranous formation.<xref ref-type="bibr" rid="article-42186.r15">[15]</xref>&#x000a0;</p>
        <p><italic toggle="yes">M pneumoniae</italic> most frequently causes community-acquired pneumonia, particularly in children aged 5&#x000a0;or older, with some regions reporting it as the cause in up to 37% of pediatric cases.<xref ref-type="bibr" rid="article-42186.r1">[1]</xref><xref ref-type="bibr" rid="article-42186.r2">[2]</xref>&#x000a0;Both&#x000a0;<italic toggle="yes">M pneumoniae</italic> and MIRM occur mostly during the winter months.<xref ref-type="bibr" rid="article-42186.r16">[16]</xref>&#x000a0;A systematic review by Canavan <italic toggle="yes">et al</italic>, using their novel proposed definition, found that&#x000a0;MIRM&#x000a0;was mostly reported in children and young adolescents with a mean age of 12.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;However, a more recent systematic review by Lofgren and Leinkeit found that MIRM cases ranged between the ages of 4&#x000a0;and 46, with a mean age of 16.<xref ref-type="bibr" rid="article-42186.r16">[16]</xref>&#x000a0;However, MIRM has also been reported in young adults.<xref ref-type="bibr" rid="article-42186.r17">[17]</xref><xref ref-type="bibr" rid="article-42186.r18">[18]</xref>&#x000a0;In the systematic review by Canavan <italic toggle="yes">et al</italic>, 60% of the identified cases of MIRM occurred in males, with 47% of patients experiencing mucositis without significant skin involvement and 34% presenting with mucositis alone&#x000a0;without any skin involvement.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;&#x000a0;</p>
        <p>The exact incidence of MIRM is not known for&#x000a0;various reasons. Importantly, until now, a distinct definition distinguishing it from other causes of mucocutaneous syndromes associated with<italic toggle="yes"> M pneumoniae</italic> infection does not exist, leading to misclassification of the syndrome. Other contributing factors include potential underreporting, often due to <italic toggle="yes">M pneumoniae</italic> not being considered in the initial diagnosis, limited availability of resources for testing, failure to identify a definitive cause, and possible lack of reporting.&#x000a0;Until 2015, the lack of a discreet definition for MIRM led to inconsistent naming conventions in publications describing cases of <italic toggle="yes">M pneumoniae</italic> infection. Examples include <italic toggle="yes">M pneumoniae&#x02013;</italic>associated SJS, Fuchs syndrome, and SJS without skin lesions.<xref ref-type="bibr" rid="article-42186.r17">[17]</xref><xref ref-type="bibr" rid="article-42186.r19">[19]</xref><xref ref-type="bibr" rid="article-42186.r20">[20]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-42186.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact pathogenesis of MIRM is&#x000a0;not completely elucidated. Proposed mechanisms include immune activation, resulting in polyclonal B-cell and antibody production, leading to immune complex deposition and complement activation, subsequently causing skin lesions.&#x000a0;Other causes could be&#x000a0;molecular mimicry&#x000a0;between <italic toggle="yes">Mycoplasm</italic>a P1-adhesion molecules and the host's keratinocytes, potentially inducing injury via antibodies or cytotoxic T cells.<xref ref-type="bibr" rid="article-42186.r12">[12]</xref><xref ref-type="bibr" rid="article-42186.r21">[21]</xref> These&#x000a0;processes differ from the mechanisms underlying erythema multiforme and SJS/TEN, which are mediated by delayed hypersensitivity reaction and Fas ligand&#x02013;mediated toxicity.<xref ref-type="bibr" rid="article-42186.r22">[22]</xref>&#x000a0;These differences can aid in the differentiation of MIRM from other cutaneous reactions.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref></p>
      </sec>
      <sec id="article-42186.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The presence of histopathological features unique to MIRM that differentiate it from erythema multiforme, SJS, and TEN remains uncertain. Erythema multiforme, SJS, and MIRM exhibit similar and overlapping histopathological characteristics, including apoptotic keratinocytes and sparse perivascular dermal infiltrates. The existence of distinct biopsy features enabling histopathological differentiation between these diseases remains controversial.</p>
        <p>Rzany et al&#x000a0;investigated specimens from erythema multiforme, SJS, and TEN and did not observe significant, consistent histologic distinctions. However, Wetter and Camilleri identified histopathologic features in drug-induced SJS that were absent in MIRM or immunization-induced SJS in some examined specimens.<xref ref-type="bibr" rid="article-42186.r23">[23]</xref><xref ref-type="bibr" rid="article-42186.r24">[24]</xref>&#x000a0;Specifically, SJS may exhibit more necrotic keratinocytes, denser dermal infiltrates, microscopic red blood cell extravasation, pigment incontinence, and parakeratosis compared to MIRM.<xref ref-type="bibr" rid="article-42186.r23">[23]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-42186.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Obtaining a thorough and detailed history of the present illness is particularly crucial. Such information can provide valuable clues aiding in the differentiation of MIRM from other mucocutaneous eruptions, such as erythema multiforme and SJS/TEN. In the case of MIRM, nearly all patients typically experience prodromal symptoms, such as fever, cough, and malaise, approximately 1 week before the onset of the rash.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;SJS/TEN, viewed as different spectra of the same underlying process, are often preceded by a prodrome of fever and upper respiratory infection symptoms. Additionally, patients with SJS/TEN usually have a history of recent exposure to new medications, such as antibiotics, nonsteroidal anti-inflammatory drugs, allopurinol, antiepileptics, and nevirapine.<xref ref-type="bibr" rid="article-42186.r25">[25]</xref>&#x000a0;This medication history may sometimes lead to a lower index of suspicion for infection during differential diagnosis evaluation (see&#x000a0;<bold>Image.</bold>&#x000a0;<italic toggle="yes">Mycoplasma pneumoniae</italic>&#x02013;Induced Rash and Mucositis).</p>
        <p>Physical examination findings in MIRM commonly reveal a predominance of mucosal rashes, with involvement of the oral mucosa (94%), ocular region (82%), and urogenital area (63%). Other mucosal sites, such as the nares and anus, may also be affected.<xref ref-type="bibr" rid="article-42186.r26">[26]</xref> Mucosal lesions are typically characterized as ulcerative or hemorrhagic and may cause discomfort. Nasal involvement may present as dense hemorrhagic crusts, sometimes manifesting as blood on the tissue. Lesions in the anus, part of the gastrointestinal mucosa, can lead to pain during defecation (see <bold>Image.</bold>
<italic toggle="yes">Mycoplasma pneumoniae</italic>&#x02013;Induced Rash and Mucositis [MIRM]).<xref ref-type="bibr" rid="article-42186.r26">[26]</xref></p>
        <p>Cutaneous non-mucosal rashes have been reported in 47% of MIRM cases, and if absent, the condition is classified as MIRM sine rash. When present, the cutaneous rash in MIRM displays distinct features compared to other mucocutaneous eruptions. MIRM rashes are typically sparse in distribution and are more commonly located in the acral regions (46%) than in the trunk (23%). The predominant morphology of the cutaneous rash in MIRM is described as vesiculobullous in 77% of cases. Additionally, both typical target lesions, characterized by 3 circumferential demarcation zones, and atypical target lesions, featuring 2 color zones, are observed in 48% of cases. Less commonly, rashes are described as papules (14%), macules (12%), or morbilliform (9%). The extent of detached skin typically involves less than 10% of the body surface area.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref></p>
        <p>In&#x000a0;contrast, erythema multiforme presents&#x000a0;initially as a cutaneous&#x000a0;acral&#x000a0;rash with macules that evolve into papules, plaques, and typical target lesions.&#x000a0;These target lesions spread centripetally to the trunk and face. Erythema multiforme minor has little or no mucous membrane involvement, and erythema multiforme major has a rash on one or more mucous membranes. SJS/TEN manifests as a rash characterized by macules, purpura, diffuse erythema, atypical target lesions, and numerous flaccid blisters.&#x000a0;These lesions are extensive in number and&#x000a0;initially more concentrated centrally and gradually coalesce, spreading to involve the face and limbs. Extensive mucous membrane involvement affecting 2 or more mucosal sites is common. The amount of skin detachment determines the extent of SJS/TEN&#x02014;SJS involves less than 10% skin detachment. Skin detachment ranging from 10% to&#x000a0;30% overlaps between SJS and TEN, whereas skin detachment exceeding&#x000a0;30% meets the criteria for TEN.<xref ref-type="bibr" rid="article-42186.r27">[27]</xref></p>
      </sec>
      <sec id="article-42186.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosing MIRM involves the presence or recent occurrence of pulmonary symptoms, often leading to clinical findings suggestive of pneumonia, which may be confirmed through clinical examination and/or chest radiography. Laboratory assessment for the cause of pneumonia should include testing for&#x000a0;elevated&#x000a0;<italic toggle="yes">M pneumoniae</italic> IgM antibodies, detecting <italic toggle="yes">M pneumoniae</italic>&#x000a0;from oropharyngeal or polymerase chain reaction (PCR) or bullae cultures, or obtaining serum cold agglutinins.<xref ref-type="bibr" rid="article-42186.r16">[16]</xref>&#x000a0;&#x000a0;</p>
        <p>The proposed definition, as outlined by Canavan et al,<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;and the&#x000a0;classic diagnostic criteria for MIRM are mentioned below.<xref ref-type="bibr" rid="article-42186.r11">[11]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Evidence of atypical <italic toggle="yes">M pneumoniae</italic> pneumonia includes:
<list list-type="bullet"><list-item><p>Signs: Fever, cough, and auscultatory or radiographic findings.</p></list-item><list-item><p>Laboratory findings: Increased <italic toggle="yes">M pneumoniae</italic> IgM antibodies, detection of <italic toggle="yes">M pneumoniae</italic> in oropharyngeal or bullae cultures or PCR, and/or serial cold agglutinins.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Skin detachment involving less than 10% of the body surface area.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Involvement of at least 2 mucosal sites.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Few vesiculobullous lesions or scattered atypical targets may be observed.</p>
          </list-item>
        </list>
        <p>Within MIRM, 3 types differ in their cutaneous, non-mucosal rash patterns&#x000a0;<xref ref-type="bibr" rid="article-42186.r13">[13]</xref><xref ref-type="bibr" rid="article-42186.r22">[22]</xref><xref ref-type="bibr" rid="article-42186.r16">[16]</xref></p>
        <p><bold>Classic MIRM:</bold>&#x000a0;This subtype meets the classic criteria outlined above and additionally presents with a non-mucosal rash, characterized by vesiculobullous lesions (77%), scattered target lesions (48%), papules (14%), macules (12%), and morbilliform eruptions (9%).</p>
        <p><bold>MIRM sine rash:</bold> This subtype fulfills the classic criteria mentioned above but lacks significant cutaneous, non-mucosal rash presence, although a few fleeting morbilliform lesions or a few vesicles may be present.</p>
        <p><bold>Severe MIRM:</bold> This subtype meets the above classic criteria, with the involvement of more than 2 mucosal sites reported. Additionally, the cutaneous rash is extensive, featuring widespread non-mucosal blisters or flat atypical target lesions.&#x000a0;</p>
      </sec>
      <sec id="article-42186.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>In the acute care setting, distinguishing MIRM from other mucocutaneous eruptions can be challenging for clinicians. Therefore, consultation with an infectious disease physician or dermatologist, or transfer to a facility with appropriate resources, may be warranted. Patients with MIRM require supportive care, including pain management for skin lesions and oral ulcerations (such as "magic mouthwash" solution or sucralfate), mucosal care, and correction of any fluid and nutritional deficiencies resulting from reduced oral intake. Severe cases of MIRM with extensive skin detachment may necessitate early transfer to a burn center.<xref ref-type="bibr" rid="article-42186.r16">[16]</xref>&#x000a0;In addition, lesions in particular mucosal areas may warrant specialty consultation with ophthalmology, otolaryngology, gastroenterology, and urology to mitigate long-term complications.&#x000a0;</p>
        <p>Although specific treatment guidelines are not tailored for MIRM, patients diagnosed with the condition often exhibit evidence of atypical pneumonia and may, therefore, benefit from antibiotic treatment.<xref ref-type="bibr" rid="article-42186.r28">[28]</xref>&#x000a0;Common oral antibiotic options for atypical pneumonia, such as macrolides, tetracyclines, and fluoroquinolones, are typically recommended, with macrolides being the preferred choice.<xref ref-type="bibr" rid="article-42186.r28">[28]</xref> Reports of macrolide resistance have been increasing globally, with varying prevalence rates across different regions. The highest resistance to the lowest prevalence of resistance is observed in the following regions&#x02014;the Western Pacific, South East Asia,&#x000a0;the United States of America, Europe, and the East Mediterranean.<xref ref-type="bibr" rid="article-42186.r29">[29]</xref> Therefore, clinicians must remain vigilant, particularly in cases of refractory Mycoplasma pneumoniae pneumonia, as alternative antibiotic regimens may need to be considered.&#x000a0;</p>
        <p>Empirical administration of corticosteroids and other immunosuppressive agents has been documented, particularly in patients with severe MIRM. Intravenous immunoglobulin (IVIG) has also been utilized in cases of MIRM with severe mucositis. In a study by Canavan et al, 35% of patients received systemic corticosteroids, and 8% received IVIG.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;In a more recent systematic review by Lofgren and Lenkeit, 77% of patients received antibiotics, 37% were treated with corticosteroids, and 11% received IVIG.<xref ref-type="bibr" rid="article-42186.r16">[16]</xref></p>
      </sec>
      <sec id="article-42186.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Common differential considerations for MIRM include other conditions that can cause similar skin findings and/or mucosal manifestations<xref ref-type="bibr" rid="article-42186.r30">[30]</xref><xref ref-type="bibr" rid="article-42186.r31">[31]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Erythema multiforme major</p>
          </list-item>
          <list-item>
            <p>SJS/TEN</p>
          </list-item>
          <list-item>
            <p>DRESS</p>
          </list-item>
          <list-item>
            <p>Staphylococcal scalded skin syndrome</p>
          </list-item>
          <list-item>
            <p>Hand-foot-and-mouth disease</p>
          </list-item>
          <list-item>
            <p>Kawasaki disease</p>
          </list-item>
          <list-item>
            <p>Herpetic gingivostomatitis</p>
          </list-item>
          <list-item>
            <p>Severe cutaneous adverse reactions (eg, drug hypersensitivity syndrome)</p>
          </list-item>
          <list-item>
            <p>Bullous systemic lupus erythematosus</p>
          </list-item>
          <list-item>
            <p>Plasma cell stomatitis</p>
          </list-item>
          <list-item>
            <p>Coxsackie virus and other enteroviruses</p>
          </list-item>
          <list-item>
            <p>SARS-CoV-2 infection</p>
          </list-item>
          <list-item>
            <p>Autoimmune diseases, such as Beh&#x000e7;et disease and systemic lupus erythematosus</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-42186.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Overall, the prognosis of MIRM is generally favorable. Only 4% of patients required admission to intensive care, with 81% experiencing complete recovery.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;The recurrence rate of MIRM is 8%.<xref ref-type="bibr" rid="article-42186.r32">[32]</xref>&#x000a0;In contrast, patients afflicted with SJS/TEN often necessitate intensive care more frequently and face higher mortality rates.<xref ref-type="bibr" rid="article-42186.r33">[33]</xref><xref ref-type="bibr" rid="article-42186.r24">[24]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-42186.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Although 81% of patients with MIRM experience a full recovery,<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;there are potential long-term sequelae, mostly involving the mucosa. Ocular mucosal damage occurs in 8.9% of patients with MIRM,&#x000a0;resulting in conjunctival shrinkage, corneal ulcerations, blindness, ocular synechiae, and loss of eyelashes.<xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;Postinflammatory pigmentary changes occurred in 5.6% of patients, while oral and genital mucosal synechiae were reported in 0.8% and 0.8% of patients, respectively. <xref ref-type="bibr" rid="article-42186.r13">[13]</xref>&#x000a0;Rare complications include persistent cutaneous lesions, B-cell lymphopenia, restrictive lung disease, and chronic obliterative bronchitis. However, while the mortality of MIRM is low, experts suspect that the vast majority of mild cases are underreported in the literature, suggesting that the true rate of morbidity and mortality is likely far lower.</p>
      </sec>
      <sec id="article-42186.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>When considering the diagnosis of MIRM, consultation with infectious diseases specialists or dermatologists may be beneficial. Additionally, obtaining consultations with otolaryngologists, ophthalmologists, gastroenterologists, and urologists may be helpful for site-dependent mucosal lesions to mitigate long-term sequelae. In cases with extensive cutaneous lesions and detachment, consulting burn specialists is advisable.</p>
      </sec>
      <sec id="article-42186.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients diagnosed with MIRM should be informed about the potential for painful mucosal lesions, which can lead to dehydration and reduced nutrient intake. In addition, it is important to keep cutaneous lesions clean to minimize the risk of secondary bacterial infection. Although the exact transmission patterns of MIRM are not well established, it is advisable for patients and close contacts of suspected <italic toggle="yes">M pneumoniae</italic> pulmonary infection to implement basic infection control measures, including droplet transmission precautions.</p>
      </sec>
      <sec id="article-42186.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>MIRM is considered a clinically distinct entity from other mucocutaneous eruptions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Historical features suggesting MIRM include a pulmonary infection approximately 1 week before the onset of the rash.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Other mucocutaneous reactions, such as erythema multiforme, often develop after a herpes simplex infection.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Although the rash of SJS/TEN may occur in the context of new medication use, it is crucial to include MIRM in the differential diagnosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The rash pattern of MIRM may differ from that of other conditions, often characterized by mucous membrane involvement.&#x000a0;In MIRM, the cutaneous rash often tends to be sparse rather than consolidated, frequently appearing in acral areas. Typically, the rash in MIRM is usually vesiculobullous or targets lesions.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Although MIRM may result in some long-term sequelae, such as mucous membrane damage and cutaneous skin changes, it generally follows a more benign course than other conditions, including SJS/TEN.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Currently, no specific guidelines exist for treating&#x000a0;MIRM, but patients may benefit from antibiotics targeting atypical pneumonia and immunosuppressive therapy with corticosteroids. Additionally, IVIG administration should be considered as part of the treatment approach.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Consulting with an infectious disease specialist or dermatologist can provide valuable guidance in directing patient care.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-42186.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>MIRM management is optimally conducted by an interprofessional team comprising infectious disease specialists, internists, primary care providers, and dermatologists. Collaborative efforts involving diagnosis, education, and patient support are crucial components of the interprofessional approach. The interprofessional team can achieve optimal outcomes by coordinating care and offering comprehensive patient education and support.</p>
        <p>Patients diagnosed with MIRM should be informed about the potential for painful mucosal lesions, which can lead to dehydration and limit oral nutrient intake. In addition, it is important to keep cutaneous lesions as clean as possible to prevent secondary bacterial infection. Although the transmission patterns of MIRM are not well-established, it is advisable for patients and close contacts of suspected <italic toggle="yes">M pneumoniae</italic> pulmonary infection to implement basic infection control measures, including droplet transmission precautions.</p>
      </sec>
      <sec id="article-42186.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42186&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42186">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/mycoplasma-pneumoniae-induced-rash-and-mucositis-mirm/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=42186">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/42186/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=42186">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-42186.s18">
        <fig id="article-42186.image.f1" position="float" orientation="portrait">
          <caption>
            <p><italic toggle="yes">&#x000a0;Mycoplasma pneumoniae</italic>&#x02013;Induced Rash and Mucositis Contributed by S Mcaninish, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Mycoplasma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-42186.s19">
        <fig id="article-42186.image.f2" position="float" orientation="portrait">
          <caption>
            <p><italic toggle="yes">Mycoplasma pneumoniae</italic>&#x02013;Induced Rash and Mucositis&#x000a0;(MIRM) Contributed by&#x000a0;S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mycoplasma__mucositis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-42186.s20">
        <title>References</title>
        <ref id="article-42186.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Thai</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ebell</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis.</article-title>
            <source>Ann Fam Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>552</fpage>
            <page-range>552-566</page-range>
            <pub-id pub-id-type="pmid">28376442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016.</article-title>
            <source>Epidemiol Infect</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>147</volume>
            <fpage>e192</fpage>
            <pub-id pub-id-type="pmid">31364532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poddighe</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Extra-pulmonary diseases related to Mycoplasma pneumoniae in children: recent insights into the pathogenesis.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>380</fpage>
            <page-range>380-387</page-range>
            <pub-id pub-id-type="pmid">29432224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drago</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ciccarese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Merlo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Trave</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Javor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rebora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parodi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Oral and cutaneous manifestations of viral and bacterial infections: Not only COVID-19 disease.</article-title>
            <source>Clin Dermatol</source>
            <year>2021</year>
            <season>May-Jun</season>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>384</fpage>
            <page-range>384-404</page-range>
            <pub-id pub-id-type="pmid">34517997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiewchengchol</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Beresford</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature.</article-title>
            <source>Pediatr Rheumatol Online J</source>
            <year>2015</year>
            <volume>13</volume>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">25587243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marquart</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kinaciyan</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Overlapping clinical presentation of Mycoplasma-induced rash and mucositis and drug-induced Stevens Johnson Syndrome: A case report.</article-title>
            <source>IDCases</source>
            <year>2023</year>
            <volume>33</volume>
            <fpage>e01888</fpage>
            <pub-id pub-id-type="pmid">37693950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frantz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Are</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Motaparthi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2021</year>
            <month>Aug</month>
            <day>28</day>
            <volume>57</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">34577817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vujic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shroff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grzelka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Posch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Monshi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sanlorenzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ortiz-Urda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rappersberger</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>595</fpage>
            <page-range>595-8</page-range>
            <pub-id pub-id-type="pmid">24665876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Brito</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title><italic>Mycoplasma pneumoniae-</italic>induced rash and mucositis: a recently described entity.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>Aug</month>
            <day>22</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">28830900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varghese</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sharain</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Skalski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramar</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mycoplasma pneumonia-associated mucositis.</article-title>
            <source>BMJ Case Rep</source>
            <year>2014</year>
            <month>Mar</month>
            <day>13</day>
            <volume>2014</volume>
            <pub-id pub-id-type="pmid">24626386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narita</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis.</article-title>
            <source>Front Microbiol</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">26858701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer Sauteur</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Theiler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buettcher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seiler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weibel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Frequency and Clinical Presentation of Mucocutaneous Disease Due to Mycoplasma pneumoniae Infection in Children With Community-Acquired Pneumonia.</article-title>
            <source>JAMA Dermatol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>156</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-150</page-range>
            <pub-id pub-id-type="pmid">31851288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canavan</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Mathes</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Frieden</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shinkai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <page-range>239-45</page-range>
            <pub-id pub-id-type="pmid">25592340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bastuji-Garin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rzany</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Shear</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Naldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roujeau</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.</article-title>
            <source>Arch Dermatol</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>129</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-6</page-range>
            <pub-id pub-id-type="pmid">8420497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandelman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Grzegorczyk</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Zejnullahu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Edson</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title><italic>Mycoplasma pneumoniae</italic>-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>ofaa437</fpage>
            <pub-id pub-id-type="pmid">33094121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lofgren</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lenkeit</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Systematic Review of the Literature.</article-title>
            <source>Spartan Med Res J</source>
            <year>2021</year>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>25284</fpage>
            <pub-id pub-id-type="pmid">34532621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alc&#x000e1;ntara-Reifs</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Nieto</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Mycoplasma pneumoniae-associated mucositis.</article-title>
            <source>CMAJ</source>
            <year>2016</year>
            <month>Jul</month>
            <day>12</day>
            <volume>188</volume>
            <issue>10</issue>
            <fpage>753</fpage>
            <pub-id pub-id-type="pmid">26927973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Figueira-Coelho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Louren&#x000e7;o</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pires</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Mendon&#x000e7;a</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Malhado</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Mycoplasma pneumoniae-associated mucositis with minimal skin manifestations.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2008</year>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>399</fpage>
            <page-range>399-403</page-range>
            <pub-id pub-id-type="pmid">18973408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tay</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Huff</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Weston</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra).</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>5 Pt 1</issue>
            <fpage>757</fpage>
            <page-range>757-60</page-range>
            <pub-id pub-id-type="pmid">8912572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00160;ternbersk&#x000fd;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tich&#x000fd;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fuchs' syndrome (Stevens-Johnson syndrome without skin involvement) in an adult male--a case report and general characteristics of the sporadically diagnosed disease.</article-title>
            <source>Acta Dermatovenerol Croat</source>
            <year>2014</year>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>284</fpage>
            <page-range>284-7</page-range>
            <pub-id pub-id-type="pmid">25580788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazori</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Nagarajan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Glick</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Recurrent reactive infectious mucocutaneous eruption (RIME): Insights from a child with three episodes.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2020</year>
            <month>May</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>545</fpage>
            <page-range>545-547</page-range>
            <pub-id pub-id-type="pmid">32172537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mart&#x000ed;nez-P&#x000e9;rez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Imbern&#x000f3;n-Moya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lobato-Berezo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Churruca-Grijelmo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mycoplasma pneumoniae-Induced Mucocutaneous Rash: A New Syndrome Distinct from Erythema Multiforme? Report of a New Case and Review of the Literature.</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>107</volume>
            <issue>7</issue>
            <fpage>e47</fpage>
            <page-range>e47-51</page-range>
            <pub-id pub-id-type="pmid">27040303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rzany</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hering</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mockenhaupt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Goerttler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ring</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;pf</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis.</article-title>
            <source>Br J Dermatol</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>135</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-11</page-range>
            <pub-id pub-id-type="pmid">8776350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wetter</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-8</page-range>
            <pub-id pub-id-type="pmid">20118388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatproedprai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wutticharoenwong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tempark</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wananukul</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital.</article-title>
            <source>Dermatol Res Pract</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>3061084</fpage>
            <pub-id pub-id-type="pmid">29853855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norton</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Diagnosing Mycoplasma pneumoniae-induced rash and mucositis (MIRM) in the emergency room.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>e67</fpage>
            <pub-id pub-id-type="pmid">26184002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noe</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Micheletti</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.</article-title>
            <source>Clin Dermatol</source>
            <year>2020</year>
            <season>Nov-Dec</season>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>607</fpage>
            <page-range>607-612</page-range>
            <pub-id pub-id-type="pmid">33341195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Byington</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Alverson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>St Peter</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Stockwell</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>JT</given-names>
              </name>
              <collab>Pediatric Infectious Diseases Society and the Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>7</issue>
            <fpage>617</fpage>
            <page-range>617-30</page-range>
            <pub-id pub-id-type="pmid">21890766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Netw Open</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>e2220949</fpage>
            <pub-id pub-id-type="pmid">35816304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mortazavi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Safi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Baharvand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rahmani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Features of Common Oral Ulcerative Lesions: An Updated Decision Tree.</article-title>
            <source>Int J Dent</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>7278925</fpage>
            <pub-id pub-id-type="pmid">27781066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Endy</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title><italic>Mycoplasma pneumoniae</italic>-Induced Rash and Mucositis (MIRM) Mimicking Beh&#x000e7;et's Disease and Paraneoplastic Pemphigus (PNP).</article-title>
            <source>Case Rep Infect Dis</source>
            <year>2022</year>
            <volume>2022</volume>
            <fpage>1013922</fpage>
            <pub-id pub-id-type="pmid">36046665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeli&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antolovi&#x00107;</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>5</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">27598215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42186.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerull</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nelle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaible</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review.</article-title>
            <source>Crit Care Med</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>1521</fpage>
            <page-range>1521-32</page-range>
            <pub-id pub-id-type="pmid">21358399</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
